Concord Drugs Ltd (CONCORD) Financials - Quarterly Results, Profit & Loss, Balance Sheet, Cash Flow Concord Drugs Ltd reported sales of ₹20.95 Cr, operating profit of ₹2.29 Cr (OPM 10.93%) and net profit of ₹1.11 Cr for the quarter ended Jun 2026. Figures in ₹ crore, consolidated where available.
CONCORD quarterly results (₹ Cr) Metric Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sales 12.37 10.8 10.39 13.61 10.28 16.99 37.9 20.95 Expenses 11.49 9.4 9.34 12.59 9.18 16.05 36.4 18.66 Operating Profit 0.88 1.4 1.05 1.02 1.1 0.94 1.5 2.29 OPM 7.11% 12.96% 10.11% 7.49% 10.7% 5.53% 3.96% 10.93% Other Income 0 0 0 0 0 0 0 0 Interest 0.47 0.5 0.61 0.49 0.49 0.34 0.4 0.4 Depreciation 0.34 0.37 0.38 0.37 0.34 0.31 0.35 0.35 Profit before tax 0.07 0.53 0.06 0.16 0.27 0.29 0.75 1.54 Tax 42.86% 58.49% 33.33% 25% 29.63% 27.59% 29.33% 27.92% Net Profit 0.04 0.23 0.04 0.12 0.19 0.22 0.53 1.11 EPS in Rs 0.04 0.23 0.04 0.12 0.19 0.17 0.4 0.84
CONCORD profit & loss, annual (₹ Cr) Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM Sales 58.96 52.08 44.92 45.24 78.77 86.12 Expenses 53.37 47.51 40.88 41.1 74.22 80.29 Operating Profit 5.59 4.57 4.04 4.14 4.55 5.83 OPM 9.48% 8.77% 8.99% 9.15% 5.78% 6.77% Other Income 0.1 0.01 0.01 0.01 0 0 Interest 1.68 1.71 1.87 2.03 1.71 1.63 Depreciation 1.76 1.63 1.56 1.43 1.37 1.35 Profit before tax 2.25 1.24 0.62 0.69 1.47 2.85 Tax 28.89% 20.97% 25.81% 50.72% 28.57% - Net Profit 1.59 0.99 0.47 0.34 1.06 2.05 EPS in Rs 1.82 1.06 0.47 0.34 0.8 1.6 Dividend Payout 0% 0% 0% 0% 0% -
CONCORD balance sheet (₹ Cr) Metric Mar 2023 Mar 2024 Mar 2025 Sep 2025 Mar 2026 Equity Capital 9.32 10 10 10 13.18 Reserves 22.38 23.82 24.11 24.42 35.34 Borrowings 16.96 17.52 19.24 17.09 13.6 Other Liabilities 9.57 7.46 11.8 17.1 12.77 Total Liabilities 58.23 58.8 65.15 68.61 74.89 Fixed Assets 12.92 11.68 12.21 11.51 11.58 CWIP 0.92 1.63 2 2.05 2.43 Investments 0.89 0.84 0.8 0.8 0.78 Other Assets 43.5 44.65 50.14 54.25 60.1 Total Assets 58.23 58.8 65.15 68.61 74.89
CONCORD cash flows (₹ Cr) Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Cash from Operating Activity 0.77 1.66 0.79 3.72 -6.77 Cash from Investing Activity -2.44 -2.27 -1.01 -2.32 -1.13 Cash from Financing Activity 1.68 0.62 0.28 -1.43 8.06 Net Cash Flow 0.01 0.02 0.07 -0.02 0.16 Free Cash Flow -1.69 0.8 -0.23 1.39 -7.94 CFO/OP 26% 45% 25% 95% -140%
CONCORD ratios Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Debtor Days 141.52 110.8 103.44 109.73 112.97 Inventory Days 151.64 178.58 251.53 261.81 137.69 Days Payable 62.25 46.92 34.02 78.95 38.15 Cash Conversion Cycle 230.9 242.47 320.95 292.59 212.52 Working Capital Days 112.48 152.43 132.77 115.78 145.92 ROCE - 6.31% 4.98% 5.2% 5.51%